廠牌列表

JCRB (cell bank)

產品貨號 產品名稱 產品規格 備註 連結
JCRB1511 KCMC-1379 human skin Human fibroblast cells derived from Beare-Stevenson syndrome patient.
JCRB1541 KCMC-1528 human
JCRB1540 KCMC-1694 human skin
JCRB9103 KD human lip fibroblast, lip
JCRB1998 KE-24 human primary colonic carcinoma poorly differentiated adenocarcinoma (signet-ring cell type) established from primary tumor.
JCRB1883 KE-3 human esophagus Human moderately differentiated squamous cell carcinoma cell line established from esophageal cancer.
JCRB1887 KE-4 human esophaqus Human poorly differentiated squamous cell carcinoma cell line established from esophageal cancer.
JCRB4003 KE-43 human primary colonic carcinoma moderately differentiated adenocarcinoma established from primary tumor. Transition to poorly differentiated adenocarcinoma by passage.
JCRB4004 KE-43C4 human primary colonic carcinoma Well-differentiated adenocarcinoma obtained by cloning KE-43
JCRB1911 KE-5 human esophagus Human well differentiated squamous cell carcinoma cell line established from esophageal cancer.
JCRB1915 KE-6 human esophagus Human well differentiated squamous cell carcinoma cell line established from esophageal cancer.
JCRB0065 KG-1 human bone marrow leukemia, acute myeloblastic
JCRB9051 KG-1 human bone marrow leukemia, acute myelogenous
JCRB0236 KG-1-C human brain mixed glioma, GFAP-negative, S-100-positive (growth is very slow).
JCRB0165 KHM-10B human peripheral blood Human Bukitt's lymphoma, ALL-L3 cell line. HLA-DR,CD19 and surface immunoglobulin(mu, lambda) positive. Ig gene rearrangements observed.
JCRB0133 KHM-1B human pleural effusion myeloma, multiple, with hyperamylasemia.
JCRB1394 KHM-2B human Peripheral blood Human acute B-cell lymphocytic leukemia cell line with two translocations t(8;14) and t(14;18).
JCRB0138 KHM-3S human pleural effusion small cell carcinoma, HTLV-1gene integration
JCRB0148 KHM-5M human pleural effusion Undifferentiated human thyroid cell line producing interl eukin 8.
JCRB0156 KHYG-1 human peripheral blood Human natural killer cell line with a p53 point mutation as a model for p53-associated leukemogenesis and a model for differentiation of NK/T cells.
Page of 74